Risks for IRONWOOD PHARMACEUTICALS INC (IRWD)

Here are some interesting risks from the recent filings of IRONWOOD PHARMACEUTICALS INC. Our algorithms work hard to highlight risks unique to this company.

In addition to the other information in this Annual Report on Form 10-K, any of the factors described below could significantly and negatively affect our business, financial condition, results of operations or prospects. The trading price of our Class A common stock may decline due to these risks.

We are highly dependent on the commercial success of LINZESS in the U.S. for the foreseeable future and we are also dependent on the commercial success of ZURAMPIC and DUZALLO; we cannot guarantee when, or if, we will attain profitability or positive cash flows.

Linaclotide and lesinurad may cause undesirable side effects or have other properties that could limit their commercial potential.

We rely entirely on contract manufacturers, our partners and other third parties to manufacture and distribute linaclotide and lesinurad. If they are unable to comply with applicable regulatory requirements, unable to source sufficient raw materials, experience manufacturing or distribution difficulties, or are otherwise unable to manufacture and distribute sufficient quantities to meet demand, our commercialization efforts may be materially harmed.

Expanding and maintaining our commercial infrastructure for lesinurad is a significant undertaking that requires substantial financial and managerial resources, and we may encounter delays or may not be successful in our efforts.